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Systemiclupuserythematosusisamultisystem,autoimmunediseaseknowntobeoneofthestrongestriskfactorsforatherosclero-
sis. Patients with SLE have an excess cardiovascular risk compared with the general population, leading to increased cardiovascular
morbidity and mortality. Although the precise explanation for this is yet to be established, it seems to be associated with the
presence of an accelerated atherosclerotic process, arising from the combination of traditional and lupus-speciﬁc risk factors.
Moreover, cardiovascular-disease associated mortality in patients with SLE has not improved over time. One of the main reasons
for this is the poor performance of standard risk stratiﬁcation tools on assessing the cardiovascular risk of patients with SLE.
Therefore, establishing alternative ways to identify patients at increased risk eﬃciently is essential. With recent developments
in several imaging techniques, the ultimate goal of cardiovascular assessment will shift from assessing symptomatic patients to
diagnosing early cardiovascular disease in asymptomatic patients which will hopefully help us to prevent its progression. This
review will focus on the current status of the imaging tools available to assess cardiac and vascular function in patients with SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a multisystem, au-
toimmune disease and is one of the strongest known risk
factorsforatherosclerosisandcoronaryarterydisease(CAD)
[1, 2]. The range of cardiovascular disease (CVD) in SLE is
broad and includes atherosclerosis, vascular inﬂammation,
Raynaud’s phenomenon, endothelial dysfunction, and a pro-
coagulant tendency associated with antiphospholipid anti-
bodies. The impact of SLE-associated CVD on both mor-
tality and morbidity is impressive: the incidence of CAD is
over 7 times greater in patients with SLE than in healthy
controls, even when matched for cardiovascular risk factors
[3]. Moreover, female patients with SLE between 35 and 44
years old have an incidence of myocardial infarction over 50
times greater than the observed in the Framingham dataset
[4].Theseﬁndingsaccountforthebimodalmortalitypattern
in SLE: an early peak (<1 year of diagnosis) associated with
renal involvement and infection and a later peak (8 years
after diagnosis) due to premature myocardial infarction [5].
In addition to an increased risk of CAD, patients with SLE
are at greater risk for stroke, with a prevalence that can reach
20% and with a high recurrence rate and greater mortality
than matched controls [6].
The reason why patients with SLE have a higher cardio-
vascular mortality and morbidity seems to be related to the
presence of an accelerated atherosclerotic process [7, 8],
which seems to be due to a complex interplay of traditional
and lupus-speciﬁc risk factors [3, 9–11]. On the one hand,
some of the factors contributing to an accelerated atheroscle-
rosis may be associated with the disease itself: the systemic
inﬂammation associated with poorly controlled SLE could
contribute to plaque destabilization. On the other hand,
patients with SLE have a high prevalence of traditional CVD
risk factors [3, 10] such as hypertension, altered lipid proﬁle
[12], and impaired glucose tolerance, which to some extent
result from chronic corticosteroid therapy [13]. However,
not only has no unequivocal correlation been established
between corticosteroid use and atherosclerosis in SLE, but
some evidence seems to suggest an increased cardiovascular
risk among patients who are under treated with steroids,
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with a higher vascular risk than steroid therapy per se [7].
The generally accepted notion is that systemic inﬂammation
related to SLE contributes both to an accelerated atheroscle-
rosis and plaque destabilization which in turn is the ma-
jor cause of acute plaque disruption responsible for acute
cardiovascular events such as myocardial infarction.
The relevance of accurate cardiovascular assessment in
patients with SLE has been emphasized by recent studies that
show that mortality associated with CVD has not improved
over time, opposing the trend seen for other causes of mor-
tality such as lupus nephritis [14, 15]. Several reasons can be
hypothesised to explain this but one of the strongest is the
poor performance of standard risk stratiﬁcation tools (based
on the Framingham risk equation) [16] in patients with
SLE, which prevents an accurate assessment of the actual
cardiovascular risk of the individual patient [9, 17]. It is,
therefore, essential to ﬁnd alternative ways to assess and
identifypatientswithSLEatincreasedriskforCVDefﬁcient-
ly. Several imaging techniques have been studied as potential
tools to assess these patients better, with particular emphasis
in noninvasive screening tools aimed at detecting subclinical
atherosclerosis.
This paper will focus on the current status of imaging
assessment of cardiac and vascular function among patients
with SLE. There are two possible roles for this type of assess-
ment. One is to identify CVD in patients with suspicious
symptoms or other good reasons to suspect CVD (e.g., heavy
smoking). The more challenging role is to diagnose CVD in
asymptomatic patients with few or no risk factors other than
SLE itself. It is important to remember that though SLE is
associated with an increased relative risk of developing CVD
compared to healthy controls, the absolute risk of developing
CVD in an individual patient remains small. For example, in
a recent multicentre study of 1249 patients recruited within
15 months of the diagnosis of SLE and followed for up to 8
years, only 74 patients developed CVD [18]. Thus, it would
be diﬃcult to justify invasive or repeated imaging to screen
for CVD in the majority of patients with SLE.
2. Assessing CardiacInvolvement
SLE-associated cardiac involvement can be divided into
4 groups: pericarditis/pericardial eﬀusion, valvular disease,
myocardial dysfunction, and coronary-artery disease (CAD).
For the purpose of this paper, we will focus only on the last
two groups.
2.1.SLE-AssociatedMyocardialDysfunction. InSLE,myocar-
d i a ld y s f u n c t i o nm a yb ed u et os e v e r a lf e a t u r e ss u c ha sC A D ,
valvular disease, drug-related cardiotoxicity (e.g., cyclophos-
phamide and chloroquine), and lupus myocarditis. After the
introduction of corticosteroid therapy, the prevalence of
autopsy-identiﬁed SLE-related myocarditis decreased from
50%–75% [19] to 25%–30% [20]. However, clinically ev-
ident lupus myocarditis is identiﬁed in less than 10% of
patients, showing the high prevalence of subclinical dis-
ease [21]. In fact, clinical manifestations of SLE-associated
myocarditis are subtle and nonspeciﬁc. The fact that systolic
function is preserved until late stages of the disease accounts
for the low sensitivity of echocardiographic assessment [22].
Although still considered the gold standard for pericardial
and valvular evaluation [22, 23], its use in lupus myocarditis
diagnosis is limited. However, it can give some indication of
left ventricle diastolic dysfunction through the presence of
impaired myocardial relaxation, decreased compliance, and
increased ﬁlling pressure [22]. Another way to assess cardiac
function is through left ventricle angiography, both by the
conventional method and by using Technetium-99m myo-
cardial perfusion imaging (SPECT), which permits accurate
assessment of left ventricle volume and function [24, 25].
However, these methods have largely been replaced by MRI
imaging [26].
The deﬁnite diagnosis of lupus myocarditis is histologi-
cal, with typical features being interstitial oedema, focal ne-
crosis/ﬁbrosis, and focal or diﬀuse inﬂammatory cellular in-
ﬁltrates [27]. However, despite being the gold standard for
diagnosis, endomyocardial biopsy cannot be used routinely
or repeatedly, particularly in asymptomatic patients. Cardiac
magnetic resonance (CMR) is sensitive to many of the chan-
ges that characterize lupus myocarditis, particularly through
T2-weighted imaging (myocardial oedema) [28, 29]a n d
early (EGE) and late (LGE) gadolinium-enhanced CMR [28,
30]. The combination of EGE, LGE, and T2 imaging sequen-
ces has been reported to have 76% sensitivity and 95.5%
speciﬁcity for the detection of myocardial inﬂammation
[28]. In addition, CMR is superior to other techniques in
assessment of left ventricle size, function, and mass, provides
high spatial resolution, is noninvasive and has high repro-
ducibility and low intra and interobserver variability [26].
In a recent study, we carried out CMR and transthoracic
echocardiography in 22 patients with SLE (11 patients with
previous CVD and 11 age-sex matched controls) [30]. We
found that CMR was more sensitive than echocardiography
for the detection of myocardial changes, especially late
gadolinium enhancement (LGE) in areas of previous infarc-
tion [30]. In contrast to a previous report [31], we did not
ﬁnd widespread small areas of LGE in the myocardial tissues
ofthesepatients.Mavrogenietal.[32]reportedLGEin18/20
patients with autoimmune rheumatic diseases (three with
SLE). Ten patients also had myocardial biopsies with a 50%
agreement between biopsy and CMR results.
CT imaging is not considered an adequate tool for eval-
uation of cardiac muscle due to radiation exposure, move-
ment artefacts and application of contrast media which pre-
ventsuseinpatientswithrenalfailureandsevereheartfailure
[33].
2.2. Coronary Artery Assessment. As stated before, SLE is
associated with a signiﬁcantly increased risk of CAD. The
presence of CAD can be evaluated directly by coronary arte-
riography and indirectly by assessing left ventricle ejection
function and ventricular wall motion through radionuclide
ventriculography, echocardiography, SPECT, and CMR [22].
2Dechocardiographyisthemostwidelyusedmethodfor
routine assessment of left ventricle ejection fraction in pa-
tients with known CAD. Other methods, such as tissue Dop-
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as superior alternatives; however, they still have not replaced
conventional echocardiography [22]. Turiel et al. [34]h a v e
proposed a global index of left ventricle function (TEI index)
aimed at systolic and diastolic left ventricle function. How-
ever, its validity in SLE has yet to be shown. Stress echocar-
diography using either exercise or pharmacological stimulus
canbeausefulmethodfordiagnosisandriskstratiﬁcationin
patients with suspected or known CAD [22].
Presently, several studies have shown the utility of MRI
imaging in assessment of CAD—though not in patients
with SLE [26, 28, 35]. Stress CMR (i.e., using dobutamine
or adenosine) is an accurate method to identify ischemia-
induced wall motion abnormalities, with a greater sensitivity
(86% versus 74%) and speciﬁcity (86% versus 70%) than
stress echocardiography [36]. In addition, perfusion defects
can be identiﬁed with gadolinium-enhanced CMRI as well as
positron emission tomography (PET) [37]a n dS P E C T[ 25].
One additional beneﬁt from PET imaging is the possibility of
identifying stable plaques as a high uptake of contrast seems
to be associated with a higher macrophage content which
would correlate with the presence of intraplaque active in-
ﬂammation [38]. However, the use of radioisotopes for PET
limits its applicability.
Electron beam CT (EB-CT) can be used to quantify cor-
onary artery calciﬁcation as a measure of coronary athe-
rosclerosis. Asanuma et al. [7] compared EB-CT ﬁndings
in 65 patients with SLE and 68 age-/sex-/ethnicity-matched
controls.Mean calciﬁcationscores was signiﬁcantly higher in
patients than controls. After adjustment for cardiac risk fac-
tors including age, sex, smoking, hypertension, triglyceride,
and homocysteine levels, patients with SLE were still 9.8
times more likely to have coronary calciﬁcation than con-
trols. The reason for this was unclear. In a subsequent paper
Kiani et al. [39] found coronary calciﬁcation in 43% of 200
women with SLE, but the only factors predicting this in
multiple logistic regression analysis were age and body mass
index. SLE disease activity was not associated with coronary
calciﬁcation. CT angiography can be used to detect plaques
in the coronary arteries. In a recent study [40], Ishimori et al.
carriedoutbothadenosinestressCMRandCTAin18female
patients with SLE who had suﬀered chest pain within the
previous six months and in 10 healthy control women. Eight
patients with SLE, but no control subjects had abnormal
perfusion on stress CMR. This was severe in 7 cases even
though none of the patients had obstructive CAD detectable
by CTA and only two of the 18 subjects had any CTA ab-
normalities. The perfusion defects were not characteristic of
coronary artery disease [40]. Thus, it seems likely that stress
CMR was detecting microvascular ischemia in patients with
SLE though larger studies are required.
Invasive methods for assessing coronary circulation such
as intravascular ultrasound (IVUS) and IVUS with virtual
histology [41], optical coherence tomography [42], coronary
angioscopy [43], and invasive MRI [44] may prove their
usefulness in the future by allowing direct plaque imaging.
However, presently their predictive value and impact on risk
stratiﬁcation is yet to be established.
3. Assessing Peripheral Vascular Involvement
Peripheral vascular involvement in SLE can be associated
with active vasculitis, endothelial dysfunction and athero-
sclerosis. For the purpose of this paper, we will focus on the
latter two.
3.1. Endothelial Dysfunction. The endothelium is the main
regulator of vascular wall homeostasis. It regulates vascular
tone and permeability, platelet and leukocyte adhesion and
aggregation, and ﬁnally, vascular thrombosis. The term
“endothelial dysfunction” describes a nonadaptive state of
phenotypic modulation characterized by a loss or deregu-
lation of the homeostatic mechanisms operative in healthy
endothelial cells [45]. Current evidence suggests that endo-
thelialdysfunctionisanearlyeventinatherogenesisandcon-
tributes to all the stages of plaque development [46]. Al-
though there are currently no imaging methods that can ef-
fectivelyassessendothelialfunction,severalfunctionalmeth-
ods have been developed to try and address this issue. The
hallmark of endothelial dysfunction is an impaired endo-
thelium-dependent vasodilatation [47]. Peripheral studies
include ﬂow-mediated vasodilatation assessment [47–49],
forearm perfusion techniques, pulse wave analysis, and skin
laser Doppler ﬂowmetry [45]. Other potential markers of
endothelial dysfunction correlate with circulating procoag-
ulant, prothrombotic, and proinﬂammatory mediators, but
with the exception of C-reactive protein, evidence for their
independent predictive value is still lacking [45]. Although
veryfewstudiesofthisnaturehavebeendoneinSLE[48,49],
attenuatedﬂow-mediateddilationhasbeenaconsistentﬁnd-
ing, suggesting the presence of impaired endothelial func-
tioninthesepatientsevenbeforeovertcardiovasculardisease
is apparent.
3.2. Peripheral Vascular Assessment. The presence of com-
mon carotid artery intimal-medial thickening and discrete,
nonobstructive carotid atherosclerosis has been shown to
be independently associated with subsequent cardiovascular
risk in several longitudinal studies [50, 51].
Ultrasound assessment of carotid atherosclerosis is an
accurate, noninvasive method that allows for assessment of
arterial wall thickness and degree of plaque. Manzi et al. [52]
studied the prevalence of carotid atherosclerosis as measured
by B-mode ultrasound in 175 women with SLE, ﬁnding that
40% had at least 1 focal plaque and that more than 20% had
a at least one large plaque (>50% of the vessel diameter) or
multiple plaques with at least one medium plaque (30%–
50% of the vessel diameter). Patients with higher cumu-
lative damage measured by the modiﬁed Systemic Lupus
International Collaborative Clinics (SLICC) damage score
were more likely to have plaque, even after excluding the
cardiovascular components of the SLICC index. A strong
association between duration of use and cumulative dose
of corticosteroids was also found. Other groups, working
independentlyhavealsofoundaprevalenceofcarotidplaque
in the order of 40% in patients with SLE [8]. A longitudinal
studyfromtheManzigroup[53]assessedplaqueprogression
in 217 female patients with SLE followed for 10 years using4 Clinical and Developmental Immunology
Table 1: Overview and comparison of diﬀerent imaging methods in atherosclerotic plaque assessment (IMT: intima-media thickness; CVD:
cardiovascular disease).
Imaging method Plaque
characterization Advantages Disadvantages Published data from
patients with SLE
Carotid ultrasound IMT and plaque in
carotid arteries
No radiation
rapid-convenient
correlates with risk of
future CVD
Interpretation is operator
dependent. High frequency of
plaque in Patients with SLE
(clinical implications unclear)
Yes [22, 23, 54, 55, 58]
Magnetic resonance
imaging (MRI)
Structure of
myocardium
quantiﬁcation of lipid
content
No radiation
more sensitive than
echo for myocardial
change
Expensive
use of gadolinium limited in
patients with renal impairment
motion artefacts.
Lower spatial resolution in
vascular assessment.
Longer length of study time
Yes
[2, 13, 18, 30, 33–36]
Computed
tomography (CT)
Quantiﬁcation of
calcium, ﬁbrous and
lipid component
Noninvasive detection
of vulnerable plaques
Motion artefacts.
Contraindicated in renal
impairment
Low resolution
Yes [17, 41, 42]
Intravascular
ultrasound-based
methods
Plaque volume
Luminal and vessel
dimensions
calcium content
Good penetration
depth
complements
coronary angiography
Invasive
lower spatial resolution No
Positron emission
tomography (PET)
Plaque macrophage
content
Not established for widespread
clinical use Yes [26, 27]
Optical CT
Plaque
microstructure
(ﬁbrous cap thickness
measurement)
High spatial
resolution
Invasive
limited depth of penetration No
Invasive MR Plaque morphology
and structure
Not established for widespread
clinical use No
Coronary angioscopy Direct plaque surface
visualization
Three-dimensional
view of plaque
Superﬁcial assessment of plaque.
Risk of coronary occlusion No
ultrasound. Progression of plaque occurred in 27% of pa-
tients and, overall, the mean increase in intima-media thick-
ness was 0.011mm/year. Plaque progression was greater in
patients with SLE when compared with matched controls,
suggestingthatB-modeultrasoundmaybeausefulsurrogate
endpointinSLEclinicalmanagement[53].Importantly,this
group went on to show, for the ﬁrst time, that increase in
IMTorthepresenceofplaquepredictedincreasedriskofcar-
diovascular events [54]. They followed 224 women with
lupus but no previous cardiovascular events. Over a 10-year
followup period, 73 of them suﬀered either cardiac or ce-
rebrovascular events. In multivariable analysis, higher IMT
and presence of plaque at baseline predicted increased risk
of cardiovascular events. For IMT, the hazard ratio was 1.24
(95% CI 1.04 to 1.48) per mm increase and the hazard ratio
for presence of plaque was 5.97 (95% CI 1.52 to 23.38) [54].
Further enhancement of ultrasound assessment of carotid
plaques can be achieved using integrated backscatter analysis
of carotid-intima complex. This method has been shown to
correlate with the calcium and collagen content of vascular
wall, therefore noninvasively evaluating arterial sclerosis
[55]. However, its usefulness in SLE has not been established
[56].
High-resolution CT imaging has also been studied as an
alternative and more accurate method of assessing carotid
plaques. CT angiography has been shown to not only pro-
vide an accurate analysis of the degree of stenosis but also
to correlate with histological ﬁndings of atheromatous pla-
ques at the carotid bifurcation [57]. However, limitations as-
sociated with the use of contrast and radiation exposure are
of concern.
A potential role for MRI imaging has emerged; as its use
hasmuchlesslimitationthanCTmethods[58],andthereisa
good correlation between them. In addition to assessing inti-
mal and medial thickening, both methods yield information
concerning the pattern of plaque calciﬁcation. Whether this
correlateswiththeriskofembolicstrokeisyettobedeﬁnitely
established.
Presently, cutting edge, multimodal imaging research us-
inganimalmodelsisaimedatdeterminingwaystoaccurately
assess plaque stability [59–61]. In animal models, factors like
atherosclerotic plaque neovascularisation, thickness of ﬁ-
brous plaque, lipid-rich necrotic-core, and macrophage con-
tent have been related to an increased plaque disruption risk.
However, clinical implications in humans have not been es-
tablished.Clinical and Developmental Immunology 5
Table 1 summarises the diﬀerent methods of imaging de-
scribed in this paper with their advantages and disadvan-
tages.
4. Conclusion
Insummary,patientswithSLEhaveahighrisk ofdeveloping
CVD. Despite their relevance, traditional reversible risk fac-
tors solely cannot account for the overall cardiovascular
risk increase, which also depends on disease and treatment
related issues. In this paper, we have described a number
of technological advances that have enhanced the ability of
clinicians to assess the myocardium, coronary arteries, and
peripheral vessels in patients with CVD. For most of them,
there is little or no information about use in patients with
SLE. Some of these imaging techniques, for example, PET
scanning and CT angiography, should clearly be reserved
for patients with SLE with known CVD or very high CVD
risk (based on traditional risk factors as well as the presence
of SLE). Others, such as echocardiography and carotid ul-
trasound are convenient and noninvasive and could be used
as screening tools in asymptomatic patients though it is still
unclear how best to manage patients who have abnormal-
ities on these tests. Perhaps the best way to use these imaging
methods in the future will be in combination with assess-
ment of traditional risk factors, disease activity measure-
ments, and blood tests relevant to CVD [62]. This holistic
assessment could then be used to identify patients who
wouldbeneﬁtfrommoreaccuratebutmoreinvasiveimaging
methods such as cardiac MRI.
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